Author(s):
Nina Nurarifah, Siti Fatonah, Herwindo Pudjo Brahmantyo, Shod Abdurrachman Dzulkarnain, Shinta Oktya Wardhani
Email(s):
ninanur@ub.ac.id , sitifatonah@ub.ac.id , herwindopudjo.ipd@ub.ac.id , shodzulkarnain@unesa.ac.id , shinta_oktya.fk@ub.ac.id
DOI:
10.52711/0974-360X.2024.00233 
Address:
Convalescent Plasma Therapy Significantly improves the Clotting Kinetics of COVID-19 patients
Nina Nurarifah1, Siti Fatonah2, Herwindo Pudjo Brahmantyo1, Shod Abdurrachman Dzulkarnain3, Shinta Oktya Wardhani1
1Division of Hematology and Oncology, Department of Internal Medicine of Dr. Saiful Anwar General Hospital, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia.
2Department of Clinical Pathology of Dr. Saiful Anwar General Hospital, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia.
3Department of Chemistry, Faculty of Mathematics and Natural Science, Universitas Negeri Surabaya, Surabaya, East Java, 60231, Indonesia.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2024
ABSTRACT:
Convalescent plasma therapy is approved as an effective therapy for severe or critical cases of COVID-19. However, there is concern regarding the impact of procoagulant factors in convalescent plasma. This study aims to prove the effect of convalescent plasma therapy on the coagulation status, especially the thromboelastography, of COVID-19 patients at Dr. Saiful Anwar Malang Hospital. This study used a survey method with a cross-sectional design between the group given convalescent plasma and the control group. Data taken from medical records. The independent variable is the convalescent plasma, while the dependent variable is the thromboelastography indicator (TEG); namely R time, K time, MA, and LY30. This study also compares the correlation between convalescent plasma therapy and patients’ comorbidities including hypertension, type 2 diabetes mellitus, and renal disease. Among 305 COVID-19 patients involved in this study, only 142 patients have completed medical record data for thromboelastography evaluation. Patient characteristics analysis shows a certain tendency in patients with comorbidities to receive convalescent plasma therapy. Although many indicators of thromboelastography did not have a significant correlation with convalescent plasma therapy, such as its R time and LY30, finally this study shows K time (which represents clotting kinetics) as the most significant indicator affected by convalescent plasma therapy.
Cite this article:
Nina Nurarifah, Siti Fatonah, Herwindo Pudjo Brahmantyo, Shod Abdurrachman Dzulkarnain, Shinta Oktya Wardhani. Convalescent Plasma Therapy Significantly improves the Clotting Kinetics of COVID-19 patients. Research Journal of Pharmacy and Technology.2024; 17(4):1475-0. doi: 10.52711/0974-360X.2024.00233
Cite(Electronic):
Nina Nurarifah, Siti Fatonah, Herwindo Pudjo Brahmantyo, Shod Abdurrachman Dzulkarnain, Shinta Oktya Wardhani. Convalescent Plasma Therapy Significantly improves the Clotting Kinetics of COVID-19 patients. Research Journal of Pharmacy and Technology.2024; 17(4):1475-0. doi: 10.52711/0974-360X.2024.00233 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-4-7
REFERENCE:
1. Kishor RS, Ramhari BM. Introduction to Covid-19. Res J Sci Technol. 2020;12(4):338–45.
2. Yadav AR, Mohite SK. A Review on Severe Acute Respiratory Infection (SARI) and its Clinical Management in Suspect/Confirmed Novel Coronavirus (nCoV) Cases. Res J Pharm Dos Forms Technol. 2020;12(3):178.
3. Naresh B V. A review of the 2019 novel coronavirus (covid-19) pandemic. Asian J Pharm Res. 2020;10(3):233.
4. Sweta S, Singh N. A Decisive Review to Understand the Basic Fundamentals of Novel Corona Viruse Disease. Res J Pharmacol Pharmacodyn. 2021;13(4):118–24.
5. Mor S, Saini P, Wangnoo SK, Bawa T. Worldwide spread of COVID-19 pandemic and risk factors among co-morbid conditions especially diabetes mellitus in India. Res J Pharm Technol. 2020;13(5):2530–2.
6. Pranjal S, Raksha G, Haymanshu P, Deepak K, Mary CS. Covid-19 Test Detection by Real Time RT-PCR. Res J Pharmacol Pharmacodyn [Internet]. 2021;13(1):22–6. Available from: http://0-search.proquest.com.pugwash.lib.warwick.ac.uk/scholarly-journals/covid-19-test-detection-real-time-rt-pcr/docview/2532207359/se-2?accountid=14888%0Ahttp://webcat.warwick.ac.uk:4550/resserv??genre=article&issn=09754407&title=Research+journal+of+Ph
7. Jatain A. Data Mining for Predicting the Covid-19 Pattern. Res J Eng Technol. 2021;12(03):79–84.
8. Kumar Balai M. UK Variant COVID-19. Asian J Nurs Educ Res. 2021;11(04):601–4.
9. Dawood AA. Using Remdesivir and Dexamethasone for Treatment of SARS-CoV-2 Shortens the patient’s stay in the Hospital. Asian J Pharm Res. 2021;11(2):138–40.
10. Patel AI, Maru PR, Patel AB, Vyas AJ, Patel NK. Role of Vitamins, Minerals and Herbs in Strengthening immune system against the newly Emerging Viral Disease SARS-CoV-2. Asian J Res Pharm Sci. 2021;11(4):309–15.
11. Nand S, Neelabh N. Therapeutic effect of certain Indian medicinal compounds against the Corona Virus: An in-silico study. Asian J Pharm Res. 2021;11(3):167–72.
12. Yadav AR, Mohite SK. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Res J Pharm Dos Forms Technol. 2020;12(3):227.
13. Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19 Possibilities and Challenges. Am Med Assoc. 2020;323(16):1561–2.
14. Focosi D, Franchini M, Pirofski LA, Burnouf T, Fairweather D, Joyner MJ, et al. Covid-19 convalescent plasma is more than neutralizing antibodies: A narrative review of potential beneficial and detrimental co-factors. Viruses. 2021;13(8).
15. Klompas AM, van Helmond N, Juskewitch JE, Pruthi RK, Sexton MA, Soto JCD, et al. Coagulation profile of human COVID-19 convalescent plasma. Sci Rep [Internet]. 2022;12(1):1–7. Available from: https://doi.org/10.1038/s41598-021-04670-1
16. Franchini M, Glingani C, Morandi M, Corghi G, Cerzosimo S, Beduzzi G, et al. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial. Mayo Clin Proc Innov Qual Outcomes [Internet]. 2021;5(2):403–12. Available from: https://doi.org/10.1016/j.mayocpiqo.2021.01.010
17. Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, et al. COVID-19 and Hypercoagulability: A Review. Clin Appl Thromb. 2020;26.
18. Burton AG, Jandrey KE. Use of Thromboelastography in Clinical Practice. Vet Clin North Am - Small Anim Pract [Internet]. 2020;50(6):1397–409. Available from: https://doi.org/10.1016/j.cvsm.2020.08.001
19. Dias JD, Haney EI, Mathew BA, Lopez-Espina CG, Orr AW, Popovsky MA. New-generation thromboelastography: Comprehensive evaluation of Citrated and heparinized blood sample storage effect on clot-forming variables. Arch Pathol Lab Med. 2017;141(4):569–77.
20. Sankaravadivoo P, Rohini. Thromboelastography – A review. Res J Pharm Technol. 2018;11(3):1225–7.
21. Pan C, Chen H, Xie J, Huang Y, Yang Y, Du B, et al. The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. Front Med. 2022;9(June):1–9.
22. Ferdiana KA, Ramlan AAW, Soenarto RF, Alatas A. Thromboelastographic method for early decision on anticoagulant therapy in moderate to severe COVID-19 patients. Med J Indones [Internet]. 2022;31(2):96–101. Available from: http://dx.doi.org/10.13181/mji.oa.225890
23. von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood Adv. 2021;5(3):756–9.